Western Blot (WB)
(Western Blot analysis of Hela cell line lysate (35ug/lane) using antibody MBS647383.)
Rabbit FGFR2 Polyclonal Antibody | anti-FGFR2 antibody
FGFR2, NT (FGFR2, BEK, KGFR, KSAM, Fibroblast growth factor receptor 2, K-sam, Keratinocyte growth factor receptor, CD332)
Purified by Protein A affinity chromatography.
Purified by Protein A affinity chromatography.
Dilution: ELISA: 1:1,000
Western Blot: 1:100-500
Immunohistochemistry: 1:50-100
Flow Cytometry: 1:10-50
Immunofluorescence: 1:10-50
Western Blot (WB)
(Western Blot analysis of Hela cell line lysate (35ug/lane) using antibody MBS647383.)
Western Blot (WB)
(Western Blot analysis of Hela cell line lysate (35ug/lane) using antibody MBS647383.)
Western Blot (WB)
(Western Blot analysis of mouse NIH-3T3 cell line lysate (35ug/lane) using antibody MBS647383.)
Western Blot (WB)
(Western Blot analysis of mouse NIH-3T3 cell line lysate (35ug/lane) using antibody MBS647383.)
Testing Data
Testing Data
Immunocytochemistry (ICC)
(IC staining of Hela cells using MBS647383. Alexa Fluor488-conjugated goat anti-rabbit lgG (green) was used as secondary antibody. DAPI was used to stain the cell nuclear (blue).)
Immunocytochemistry (ICC)
(IC staining of Hela cells using MBS647383. Alexa Fluor488-conjugated goat anti-rabbit lgG (green) was used as secondary antibody. DAPI was used to stain the cell nuclear (blue).)
Flow Cytometry (FC/FACS)
(Flow Cytometric analysis of NCI-H460 cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibody was used for the analysis.)
Flow Cytometry (FC/FACS)
(Flow Cytometric analysis of NCI-H460 cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibody was used for the analysis.)
Testing Data
(C:FGFR2/isolectinB4 (C) and FGFR1/isolectinB4 (D) staining of apparent mesenchymal cells and the subpopulation of endothelial cells. Virtually all other dispersed apparent mesenchymal cells express FGFR1 and FGFR2 (merged image in E). F: FGFR2 (F) and FGFR1 (G) staining in clustered cells of epithelial origin (inferred by morphology here) demonstrating that epithelial cells express both FGFR1 and FGFR2 (merged image with DAPI staining in H).)
Testing Data
(C:FGFR2/isolectinB4 (C) and FGFR1/isolectinB4 (D) staining of apparent mesenchymal cells and the subpopulation of endothelial cells. Virtually all other dispersed apparent mesenchymal cells express FGFR1 and FGFR2 (merged image in E). F: FGFR2 (F) and FGFR1 (G) staining in clustered cells of epithelial origin (inferred by morphology here) demonstrating that epithelial cells express both FGFR1 and FGFR2 (merged image with DAPI staining in H).)
NCBI and Uniprot Product Information
NCBI Description
The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009]
Uniprot Description
Function: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. Ref.25 Ref.26 Ref.27 Ref.28 Ref.29 Ref.30 Ref.31 Ref.32 Ref.33 Ref.34 Ref.35 Ref.36 Ref.38 Ref.40 Ref.47
Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. Ref.31 Ref.35 Ref.49 Ref.51
Enzyme regulation: Present in an inactive conformation in the absence of bound ligand. Ligand binding leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by ARQ 523 and ARQ 069; these compounds maintain the kinase in an inactive conformation and inhibit autophosphorylation. Ref.48 Ref.51
Subunit structure: Monomer. Homodimer after ligand binding. Interacts predominantly with FGF1 and FGF2, but can also interact with FGF3, FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in vitro). Ligand specificity is determined by tissue-specific expression of isoforms, and differences in the third Ig-like domain are crucial for ligand specificity. Isoform 1 has high affinity for FGF1 and FGF2, but low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7, and has much higher affinity for FGF7 than isoform 1 (in vitro). Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB increases the affinity for FGF19 and FGF21. Interacts with PLCG1, GRB2 and PAK4. Ref.6 Ref.7 Ref.25 Ref.26 Ref.27 Ref.28 Ref.29 Ref.30 Ref.31 Ref.32 Ref.36 Ref.43 Ref.47 Ref.49
Subcellular location: Cell membrane; Single-pass type I membrane protein. Golgi apparatus. Cytoplasmic vesicle. Note: Detected on osteoblast plasma membrane lipid rafts. After ligand binding, the activated receptor is rapidly internalized and degraded. Ref.31 Ref.33 Ref.34 Ref.36Isoform 1: Cell membrane; Single-pass type I membrane protein. Note: After ligand binding, the activated receptor is rapidly internalized and degraded. Ref.31 Ref.33 Ref.34 Ref.36Isoform 3: Cell membrane; Single-pass type I membrane protein. Note: After ligand binding, the activated receptor is rapidly internalized and degraded. Ref.31 Ref.33 Ref.34 Ref.36Isoform 14: Secreted Ref.31 Ref.33 Ref.34 Ref.36. Isoform 19: Secreted Ref.31 Ref.33 Ref.34 Ref.36.
Domain: The second and third Ig-like domains directly interact with fibroblast growth factors (FGF) and heparan sulfate proteoglycans. Alternative splicing events affecting the third Ig-like domain are crucial for ligand selectivity. Ref.6 Ref.7 Ref.25
Post-translational modification: Autophosphorylated. Binding of FGF family members together with heparan sulfate proteoglycan or heparin promotes receptor dimerization and autophosphorylation on several tyrosine residues. Autophosphorylation occurs in trans between the two FGFR molecules present in the dimer. Phosphorylation at Tyr-769 is essential for interaction with PLCG1. Ref.29 Ref.31 Ref.33 Ref.35 Ref.48 Ref.49 Ref.50 Ref.51N-glycosylated in the endoplasmic reticulum. The N-glycan chains undergo further maturation to an Endo H-resistant form in the Golgi apparatus. Ref.31 Ref.33Ubiquitinated. FGFR2 is rapidly ubiquitinated after autophosphorylation, leading to internalization and degradation. Subject to degradation both in lysosomes and by the proteasome. Ref.28 Ref.31 Ref.38
Involvement in disease: Crouzon syndrome (CS) [MIM:123500]: An autosomal dominant syndrome characterized by craniosynostosis, hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.10 Ref.24 Ref.40 Ref.48 Ref.52 Ref.53 Ref.54 Ref.55 Ref.59 Ref.60 Ref.61 Ref.65 Ref.66 Ref.67 Ref.68 Ref.72 Ref.75 Ref.78 Ref.79Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.53 Ref.55 Ref.59 Ref.64 Ref.67Apert syndrome (APRS) [MIM:101200]: A syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.21 Ref.28 Ref.40 Ref.45 Ref.57 Ref.65 Ref.67 Ref.69 Ref.79Pfeiffer syndrome (PS) [MIM:101600]: A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.31 Ref.40 Ref.48 Ref.56 Ref.58 Ref.59 Ref.63 Ref.65 Ref.70 Ref.71 Ref.73 Ref.74 Ref.75 Ref.79Beare-Stevenson cutis gyrata syndrome (BSTVS) [MIM:123790]: An autosomal dominant disease characterized by craniofacial anomalies, particularly craniosynostosis, and ear defects, cutis gyrata, acanthosis nigricans, anogenital anomalies, skin tags, and prominent umbilical stump. The skin furrows have a corrugated appearance and are widespread. Cutis gyrata variably affects the scalp, forehead, face, preauricular area, neck, trunk, hands, and feet.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.62 Ref.80Familial scaphocephaly syndrome (FSPC) [MIM:609579]: An autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.48 Ref.81Lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]: An autosomal dominant ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Lacrimo-auriculo-dento-digital syndrome is characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.49 Ref.82Antley-Bixler syndrome, without genital anomalies or disordered steroidogenesis (ABS2) [MIM:207410]: A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.77Bent bone dysplasia syndrome (BBDS) [MIM:614592]: A perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.85
Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.Contains 3 Ig-like C2-type (immunoglobulin-like) domains.Contains 1 protein kinase domain.
Sequence caution: The sequence BAG57383.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally shortened.
Research Articles on FGFR2
Similar Products
Product Notes
The FGFR2 fgfr2 (Catalog #AAA647383) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The FGFR2, NT (FGFR2, BEK, KGFR, KSAM, Fibroblast growth factor receptor 2, K-sam, Keratinocyte growth factor receptor, CD332) reacts with Human, Monkey, Mouse, Rat and may cross-react with other species as described in the data sheet. AAA Biotech's FGFR2 can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB), Immunohistochemistry (IHC), Flow Cytometry (FC/FACS), Immunofluorescence (IF). Suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence, Flow Cytometry, ELISA Dilution: ELISA: 1:1,000 Western Blot: 1:100-500 Immunohistochemistry: 1:50-100 Flow Cytometry: 1:10-50 Immunofluorescence: 1:10-50. Researchers should empirically determine the suitability of the FGFR2 fgfr2 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "FGFR2, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
